Evaluation of the Polysaccharide “Immeran” Activity in Syrian hamsters’ Model of SARS-CoV-2-Reference-Cited by-同舟云学术

Evaluation of the Polysaccharide “Immeran” Activity in Syrian hamsters’ Model of SARS-CoV-2

Published:2024-03-09 Issue:3 Volume:16 Page:423
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Generalova Liubov Viktorovna¹,Laryushkin Denis Pavlovich²^ORCID,Leneva Irina Anatolievna³,Ivanina Anna Valerievna³,Trunova Galina Vladimirovna⁴,Dolinnyi Sergei Vladimirovich¹,Generalov Evgenii Aleksandrovich⁵^ORCID

Affiliation:

1. Faculty of Medicine, Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia

2. Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Institute of Cell Biophysics of the Russian Academy of Sciences, 142290 Pushchino, Russia

3. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia

4. Federal State Budgetary Institution National Medical Research Radiological Center (FSBI NMRRC) of the Ministry of Health of the Russian Federation, P.A. Hertsen Moscow, Oncology Research Institute, 125284 Moscow, Russia

5. Faculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia

Abstract

COVID-19 is a highly contagious respiratory disease with a high number of lethal cases in humans, which causes the need to search for new therapeutic agents. Polysaccharides could be one of the prospective types of molecules with a large variety of biological activities, especially antiviral. The aim of this work was to study the specific antiviral activity of the drug “Immeran” on a model of a new coronavirus infection SARS-CoV-2 in hamsters. Based on the second experiment, intraperitoneal treatment with the drug according to a treatment regimen in doses of 500 and 1000 μg/kg (administration after an hour, then once a day every other day, a total of 3 administrations) was effective, reliably suppressing the replication of the virus in the lungs and, at a dose of 1000 μg/kg, prevented weight loss in animals. In all cases, the treatment stimulated the formation of virus-neutralizing antibodies to the SARS-CoV-2 virus, which suggests that the drug possesses adjuvant properties.

Funder

LLC SPC Gemma-B

ICB RAS

Publisher

MDPI AG

Link

https://www.mdpi.com/1999-4915/16/3/423/pdf

Reference35 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

2. COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS;Gibson;Med. J. Aust.,2020

3. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review;Sanders;JAMA,2020

4. The evolution of SARS-CoV-2;Markov;Nat. Rev. Microbiol.,2023

5. Favresse, J. (2021). Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses, 13.